Related references
Note: Only part of the references are listed.Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis
Marlon Perera et al.
EUROPEAN UROLOGY (2020)
Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial
Patrick Bowden et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Patterns of Progression After 68 Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer
Alexander Soldatov et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Kim N. Chi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A clinician-centred programme for behaviour change in the optimal use of staging investigations for newly diagnosed prostate cancer
Alison B. Rutledge et al.
BJU INTERNATIONAL (2018)
A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol
Michael S. Hofman et al.
BJU INTERNATIONAL (2018)
Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial
Shankar Siva et al.
EUROPEAN UROLOGY (2018)
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
Piet Ost et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases
Giuseppe Fanetti et al.
MEDICAL ONCOLOGY (2018)
Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group
Hester Lieng et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography
Andrew Kneebone et al.
EUROPEAN UROLOGY ONCOLOGY (2018)
Gotta Catch 'em All'', or Do We? Pokemet Approach to Metastatic Prostate Cancer
Declan G. Murphy et al.
EUROPEAN UROLOGY (2017)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)
Gregor Habl et al.
BMC CANCER (2017)
The use of 68 Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer
Greta Meredith et al.
BJU INTERNATIONAL (2016)
Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis
Piet Ost et al.
EUROPEAN UROLOGY (2016)
Adverse effects of androgen-deprivation therapy in prostate cancer and their management
Handoo Rhee et al.
BJU INTERNATIONAL (2015)
Metastasis-directed Therapy of Regional and Distant Recurrences After Curative Treatment of Prostate Cancer: A Systematic Review of the Literature
Piet Ost et al.
EUROPEAN UROLOGY (2015)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A trial in design: CORE - Conventional Care or Radioablation in the treatment of Extracranial metastases
K. Aitken et al.
LUNG CANCER (2014)
Stereotactic body radiation therapy: The report of AAPM Task Group 101
Stanley H. Benedict et al.
MEDICAL PHYSICS (2010)